The effect of indacaterol on exercise tolelability

Phase 4

• Conditions: chronic obstructive lung disease

• Registration Number: JPRN-UMIN000009657
• Lead Sponsor: PO Hagakure Respiratory Care Net

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) severe medical condition other than COPD. 2) arthral disease with pain which impairs walking. 3) a person who cannot uderstand the purpose and the method of this clinical study 4) a person who was assessed inappropriate for this clinical study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The improvement of endurance shattle walking test distance 30 days after the start of daily indacaterol.

Secondary Outcome Measures

Name	Time	Method
1 The improvement of COPD assessment test score and dynamic hyperinflation 30 days after the start of daily indacaterol. 2. The improvement of FEV1 after indacaterol inhalation.